Vimarsana
Biggest News Aggregation in the World

Page 3 - John Savin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from John Savin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In John Savin Today - Breaking & Trending Today

Proactive's John Savin publishes fresh research note on Oxford Cannabinoid Technologies - Vimarsana News

Proactive's John Savin publishes fresh research note on Oxford Cannabinoid Technologies

Proactive research analyst John Savin speaks to Thomas Warner after publishing a new report on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP,...

Creo Medical Group currently worth "about £100mln", says Proactive research analyst - Vimarsana News

Creo Medical Group currently worth "about £100mln", says Proactive research analyst

Proactive research analyst John Savin speaks to Thomas Warner about his latest research note on Creo Medical Group PLC (AIM:CREO). He gives his take on how...

Proactive research analyst John Savin on Oxford Cannabinoid Technologies - Vimarsana News

Proactive research analyst John Savin on Oxford Cannabinoid Technologies

Proactive research analyst John Savin speaks to Thomas Warner after publishing a new report on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP,...

EQS-News: Proactive research analyst John Savin on Oxford Cannabinoid Technologies - Vimarsana News

EQS-News: Proactive research analyst John Savin on Oxford Cannabinoid Technologies

EQS-News: Oxford Cannabinoid Technologies Holdings PLC Proactive research analyst John Savin on Oxford Cannabinoid Technologies 15.12.2022 / 13:30 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive UK Ltd+44 20 7989 0813uk@proactiveinvestors....

Shield Therapeutics: Ready to market fully approved oral iron product - Vimarsana News

Shield Therapeutics: Ready to market fully approved oral iron product

Proactive Research analyst John Savin explains the investment case for Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF), which directly sells a fully approved...